Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- ChecktodayChange DetectedThe page now shows Revision: v3.0.2, replacing v3.0.1; the 'Back to Top' element has been removed.SummaryDifference0.1%
- Check7 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content or other important elements.SummaryDifference0.1%
- Check15 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new terms related to ovarian cancer and various chemical compounds. Notably, the previous version's references to ovarian epithelial cancer and several antineoplastic agents have been removed.SummaryDifference2%
- Check22 days agoChange DetectedThe reference to the study 'Nivolumab plus ipilimumab in advanced melanoma' has been completely removed from the page.SummaryDifference0.2%
- Check29 days agoChange DetectedThe web page has been updated from version 2.16.11 to version 2.16.12.SummaryDifference0.0%
- Check36 days agoChange DetectedThe web page has been updated from version 2.16.10 to version 2.16.11, indicating a revision in the content.SummaryDifference0.0%
Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.